Psoriatic Arthritis
Patients with PsA respond better to biologic DMARDs vs. those with RA at 12 years
A greater percentage of patients with psoriatic arthritis achieve remission with biologic therapy than those with rheumatoid arthritis, at both 1- and 12-year follow-up, according to data published in Arthritis Research & Therapy.
Depression rate lower with apremilast treatment for psoriasis, psoriatic arthritis
European Commission approves upadacitinib for PsA, ankylosing spondylitis
The European Commission has extended approval for AbbVie’s upadacitinib 15 mg to treat adult patients with active psoriatic arthritis and adult patients with active ankylosing spondylitis, according to a company press release.
TNF inhibitors do not increase solid cancer risk in PsA
There is no increased risk for solid cancer, or eight common cancer types, among patients with psoriatic arthritis who receive TNF inhibitors, according to data published in Rheumatology.
MAXIMISE: Secukinumab significantly improves signs, symptoms of axial disease in PsA
Secukinumab in doses of 300 and 150 mg significantly improves signs and symptoms of axial disease, compared with placebo, in patients with psoriatic arthritis with axial manifestations, according to data.
Taking the journey together: Shared decision-making in psoriatic disease
The doctor-patient relationship is evolving from a paternalistic to a collaborative model of care across the rheumatology specialty.
Upadacitinib improves PsA signs, symptoms in DMARD-refractory patients
Upadacitinib, in doses of either 15 or 30 mg, is superior to placebo in improving signs and symptoms of active psoriatic arthritis among patients who are intolerant, or had an inadequate response, to a biologic DMARD, according to data.
Methotrexate discontinuation feasible in patients with stable PsA receiving tofacitinib
Among patients with stable psoriatic arthritis receiving tofacitinib with methotrexate, some may be able to discontinue methotrexate without changes in disease activity or safety, according to data published in The Lancet Rheumatology.
SLE twice as prevalent among patients with psoriatic arthritis
Systemic lupus erythematosus is 2.3 times more prevalent among patients with psoriatic arthritis compared with the general population, according to data published in The Journal of Rheumatology.
Apremilast monotherapy effective in oligoarticular psoriatic arthritis
Treatment with apremilast alone is effective in patients with oligoarticular psoriatic arthritis, according to data published in The Journal of Rheumatology.